FDA approves breakthrough drug to treat advanced pancreatic cancer

The FDA approved daraxonrasib, a breakthrough targeted therapy for metastatic pancreatic adenocarcinoma, showing nearly double median survival in late-stage trials compared to chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.